SynthesisPloS one2018
The role of surgery in stage I to III small cell lung cancer: A systematic review and meta-analysis.
Synthesis in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A Comprehensive Study on Clinical Outcomes and Safety of Neoadjuvant Immunotherapy Combined With Chemotherapy in Limited-Stage Small Cell Lung Cancer.Thoracic cancer · 2025Pooled it
- Survival analysis of surgical versus nonsurgical treatment in stage I to III small cell lung cancer in the last 20 years: A systematic review and meta-analysis.Thoracic cancer · 2023Pooled it
- A study of postoperative pathologic complete response (pCR) following neoadjuvant chemoimmunotherapy in limited-stage small cell lung cancer (LS-SCLC).Journal of cardiothoracic surgery · 2026Article
- Treatment pathways of lung cancer patients in the Czech Republic: insights from administrative claims data.BMJ open respiratory research · 2026Article
- Efficacy and safety of neoadjuvant chemotherapy with or without PD-L1/PD-1 inhibitors in surgically limited-stage small-cell lung cancer.Translational lung cancer research · 2025Article
- Development and validation of a serum inflammatory biomarker-driven machine-learning model for prognostic stratification in surgical limited-stage small cell lung cancer.Translational lung cancer research · 2025Article
- Sevoflurane induces CaCytotechnology · 2025Article
- A retrospective real-world single-arm study evaluating the efficacy and safety of neoadjuvant chemotherapy in patients with selected limited-stage small-cell lung cancer.Translational lung cancer research · 2025Article
- Genomic and immunological profiling reveals novel prognostic biomarkers for limited-stage small cell lung cancer.Discover oncology · 2025Article
- Prophylactic cranial irradiation improved the prognosis in pT1-2N0M0 small cell lung cancers after complete resection: a retrospective real-world study.BMC cancer · 2025Article
- Survival outcomes of surgery and adjuvant chemotherapy in early-stage small cell and large cell lung cancer: a novel focus on tumors less than 1 cm.Discover oncology · 2025Article
- Preoperative immunochemotherapy versus chemotherapy as first-line treatment for patients with stage I-IIIB small-cell lung cancer.BMC cancer · 2025Article
- Improved survival of patients with stage III small-cell lung cancer with primary resection: A SEER-based analysis.Translational oncology · 2024Article
- Role of Surgery in Potentially Resectable Small-Cell Lung Cancer Based on the Eighth Edition of the TNM Classification: A Population Study of the US SEER Database.The clinical respiratory journal · 2024Article
- Different treatment modalities on the prognosis of patients with stage I-IIIa small cell lung cancer: a population based study.Journal of thoracic disease · 2024Article
- CD3, CD8, IFN-γ, tumor and stroma inflammatory cells as prognostic indicators for surgically resected SCLC: evidences from a 10-year retrospective study and immunohistochemical analysis.Clinical and experimental medicine · 2024Article
- Prognostic factors in clinical stage IIIA small cell lung cancer: An analysis of a population-based cancer registry in Taiwan.PloS one · 2024Article
- Progress in radiotherapy for small-cell lung cancer.Precision radiation oncology · 2023Review
- Lobectomy versus sublobar resection for stage I (T1-T2aN0M0) small cell lung cancer: A SEER population-based propensity score matching analysis.Cancer medicine · 2023Article
- Surgery is a promising strategy for improving overall survival for stage III-N2 non-small cell lung cancer patients.Journal of thoracic disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of surgery in treating small cell lung cancer (SCLC) remains controversial. This meta-analysis aims to determine whether surgical-based treatment improves survival in comparison to radiotherapy, chemotherapy, and chemoradiotherapy for stage I to III SCLC.
methodsPubMed, PubMed Central, EMBASE, Web of Science, and Cochrane Library were searched for relevant articles. The main outcome were overall survival (OS), reported as hazard ratios (HRs), and 95% confidence intervals (CIs).
resultsTwo randomized control trials (RCTs) and 13 retrospective studies that included a total of 41,483 patients were eligible. Surgical resection significantly improved OS when compared to non-surgical treatment in retrospective studies (HR = 0.56, 95% CI: 0.49-0.64, P < 0.001), but not in the 2 "older" RCTs (HR = 0.77, 95% CI: 0.32-1.84, P = 0.55). In the subgroup analysis for retrospective studies, surgical resection was associated with superior OS in stage I (HR = 0.56, 95% CI: 0.49-0.64, P < 0.001), stage II (HR = 0.75, 95% CI: 0.57-0.99, P = 0.04), and stage III diseases (HR = 0.70, 95% CI: 0.56-0.88, P = 0.002). Sublobar resection resulted in worse OS than a lobectomy (HR = 0.64, 95% CI: 0.56-0.74, P < 0.001) for patients undergoing surgical resection.
conclusionsSurgery-based multi-modality treatment appears to be associated with a favorable survival advantage in stage I and selected stage II to III SCLC. Lobectomy is likely to provide superior OS when compared to sublobar resection. Further prospective RCTs are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.